Boehringer Ingelheim, a global leader in biopharmaceuticals, has officially launched local production of its flagship anti-diabetic drug Tradjenta® (linagliptin) at its Zhangjiang human drug production base in Shanghai.

This strategic step deepens the company's presence in China, signifying a shift from primarily commercial operations to a fully integrated industrial chain.

By localizing production, Boehringer Ingelheim aims to ensure a more stable and resilient supply of Tradjenta® in the Chinese market while enhancing the Shanghai base's capacity, further solidifying its role as a key Asia-Pacific supply hub.

The inauguration ceremony was attended by senior leadership, including Hubertus von Baumbach, chairman of the shareholders' committee of Boehringer Ingelheim, and Mohammed Tawil, president and CEO of Boehringer Ingelheim Greater China.

Marking the company's 30th anniversary in China, Mohammed Tawil highlighted the significance of localizing Tradjenta® production in Shanghai, noting that China now serves as both a vital market and an innovation center for Boehringer Ingelheim’s global operations.

Over the past three decades, Boehringer Ingelheim has steadily expanded its investment in China, building a full-value-chain presence spanning early-stage R&D, clinical development, manufacturing, commercialization, and external innovation. Looking ahead, the company plans to invest over 5 billion yuan ($701.87 million) in R&D in China over the next five years.

Demonstrating its ongoing commitment, Boehringer Ingelheim will participate in the China International Import Expo for the seventh consecutive year this autumn, showcasing newly launched innovative products and reinforcing its long-term presence in the Chinese market.

 

Source: Official WeChat account of Boehringer Ingelheim China at "bichina"